Patent ID: 11896574
Assignee: nan
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 15:
16. A method of treatment or prevention of a metabolic disorder in a cat comprising administering to the cat the SGLT-2 inhibitor 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene (Velagliflozin) or a pharmaceutically acceptable form thereof represented by the following formula:, wherein the metabolic disorder is selected from the group consisting of pre-diabetes, diabetes mellitus type 1, diabetes mellitus type 2, clinical conditions associated with pre-diabetes, diabetes type 1 or diabetes type 2, and combinations thereof;
the SGLT-2 inhibitor or a pharmaceutically acceptable form thereof is administered at a dose no greater than 5 mg/kg body mass per day; and
the administering results in a reduction of hyperglycemia and hyperglycemia associated clinical signs in the cat with diabetes.